X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development FDA Approvals

U.S. FDA confirms Pfizer COVID vaccine safe & effective

Content Team by Content Team
9th December 2020
in FDA Approvals, News
U.S. FDA confirms Pfizer COVID vaccine safe & effective

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The US FDA gives a green signal to Pfizer-BioNTech COVID-19 vaccine as it declairs it to be safe and effective. A US roll-out of the vaccine is expected post-approval from an outside panel of scientific advisers and with the way things are moving, the authorization might come as early as Friday this week.

As COVID cases continue to surge in the US, Food & Drug Administration-FDA is all set to take a momentous decision in its history. In its 53-page briefing document that has been recently published, the vaccine meets the standard when it comes to emergency use authorization.

In the US, the hospitals are preparing themselves to receive the COVID-19 vaccine shipments. One may expect the vaccine roll-out decision by the weekend. All this may well take an actual shape post a review of the FDA report by an outside panel of scientific advisers. The analysis shall take place with the manufacturers of the vaccine, Pfizer & BioNTech. A favourable recommendation is expected by the panellists, which will, in turn, help the FDA to grant emergency authorization for vaccine distribution. With the way things are moving, the authorization might come as early as Friday this week.

There is a lot of positivity surrounding the report which suggests that the two-dose vaccine has started to show effective results in the first dose itself. Once approval is received by the FDA, effective dose authorization can be put in place which will allow some adults to receive the vaccine. However, the agency will continue to evaluate the date and monitor results simultaneously. Alex Azar, Health and Human Service Secretary has been quoted as saying that once the panel formally votes OK to the vaccine, it will not take much time before FDA announces its authorization. That said, he further added that the vaccine will be in line with the FDA’s gold-standard process.

The authorization will come as a step that otherwise takes a decade to get completed. Pfizer in its final analysis of the phase 3 trial had a sample of 43000 participants and found that the vaccine was 95% effective in fending off the disease. As per the US officials, they shall distribute the vaccine within 24 hours of the authorization coming-in. However, it will take months to immunize everyone who wants to get vaccinated. As Drug Makers & State Authorities are gearing up to get the vaccine distributed post the approval by the FDA, the process is expected to start in about a week time. The first doses are expected to be shipped within hours of a decision with a target to distribute 6.4 million doses in the first week itself. The FDA report in the analysis was unable to determine whether people who had suffered from COVID-19 got benefited from the vaccination. Many questions remain unanswered like how long the protection will last and whether the vaccine will prevent people who are infected despite vaccination from spreading the dreaded disease.

It is well to be noted that the US has approached Pfizer for 100 million doses last week, but was informed that the supply may not be available until June.

Previous Post

COVID-19 Vaccine - Has UK created the pressure to rush on other countries?

Next Post

Allergy Alarm Raised On Pfizer-BioNTech COVID-19 Vaccine

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post
Allergy Alarm Raised On Pfizer-BioNTech COVID-19 Vaccine

Allergy Alarm Raised On Pfizer-BioNTech COVID-19 Vaccine

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In